Welcome to Roivant

Reinventing the discovery, development, and commercialization of new medicines

About Us

We develop transformative medicines and technologies by building agile, focused companies called Vants.

Learn about us

positive Phase 3 trials since 2019

FDA approvals

Our companies

Our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.

We employ technology across discovery, development, and commercialization.

Learn about our companies

Immunovant

Advancing potentially transformative therapies for autoimmune diseases

Priovant

Developing targeted therapies for patients with severe autoimmune disease

Pulmovant

Committed to transforming the lives of patients with pulmonary diseases

About Roivant

News and Press Releases

Read the latest from Roivant and the media.

Oncology biotech Epitopea licenses Genevant nucleic acid delivery tech for up to $123M

Read the full article here

To develop RNA medicines targeting a proprietary bundle of tumor antigens, Epitopea is tapping nucleic acid delivery specialist Genevant Sciences in a deal worth up to $123.5 million. Genevant can earn that sum through upfront and contingent milestone payments per product along with tiered royalties on future sales, according to a Dec. 19 release. The goal of the deal is to develop new mRNA-lipid nanoparticle (LNP) therapies for an undisclosed cancer indication, the companies said.

Epitopea teams up with Genevant in $124 million deal

Read the full article here

Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. The collaboration could see Genevant earn up to $124 million in upfront and milestone payments, alongside royalties on future sales. The companies aim to create mRNA-lipid nanoparticle therapies for an undisclosed cancer indication, with Epitopea gaining a nonexclusive global license to related delivery technology.

Idorsia’s Tryvio deal delay; Galectin’s liver drug disappoints

Read the full article here

Epitopea, Genevant ink cancer therapy pact: Epitopea will use Genevant’s lipid nanoparticle technology to develop RNA-based immunotherapies targeting certain proprietary tumor-specific antigens. The Canadian biotech could get up to $123.5 million in upfront and milestone fees for each product it makes with Epitopea.

Roivant unveils new ‘vant’ to take forward Bayer’s inhaled hypertension med

Read the full article here

Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to a phase 2-ready pulmonary hypertension drug. … “Mosliciguat has the incredibly rare advantage of potential differentiation across three separate key areas—efficacy, safety and convenience in administration,” Roivant’s Gline said in a release.

Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

Read the full article here

Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn deal. Organon will pay $175m upfront for the business as part of the transaction, which is expected to close in the fourth quarter of this year, as per an 18 September press release. Shares in both Organon and Roivant were down at close compared to their respective market opening prices on the day of the announcement.